Does the efficacy of BCG decline with time since vaccination?

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 3, 1998, Pages 200-207

  Sterne, J A C ^a   Rodrigues, L C ^b   Guedes, I N ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

BCG vaccine; Meta analysis; Review; Tuberculosis

Indexed keywords

BCG VACCINE;

ARTICLE; BCG VACCINATION; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; TUBERCULIN TEST; TUBERCULOSIS;

BCG VACCINE; HUMANS; TIME FACTORS; TUBERCULOSIS; VACCINATION;

EID: 0031939337     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Rodrigues L C, Smith P G. Tuberculosis in developing countries and methods for its control. Trans Roy Soc Trop Med Hyg 1990; 84: 739-744.
2. Hart P D, Sutherland I. BCG and Vole Bacillus Vaccines in the prevention of tuberculosis in adolescence and early adult life: Final report to the Medical Research Council, Brit Med J 1977; 2: 293-295.
3. Comstock G W. Field trials of tuberculosis: How could we have done them better? Controlled Clin Trials 1994; 15: 247-276.
4. Colditz G A, Berkey C S, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96: 29-35.
5. Rodrigues L C, Diwan V K, Wheeler J G. Protective effect of BCG against tuberculosis meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22: 1154-1158.
6. Colditz G A, Brewer T F, Berkey C S, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. JAMA 1994; 271: 698-702.
7. Fine P E M, BCG vaccination against tuberculosis and leprosy. Br Med Bull 1988; 44: 691-703.
8. Fine P E M, Rodrigues L C. Modern vaccines. Mycobacterial Diseases. Lancet 1990; 335: 1016-1020.
9. Ferguson R G, Simes A B. BCG vaccination in Indian infants of Saskatchewan. Tubercle 1949; 30: 5-11.
10. Aronson J D, Palmer C E. Experience with BCG vaccine in the control of tuberculosis among North American Indians. Public Health Rep 1946; 61: 802-820.
11. Aronson J D. Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc 1948; 58: 255-281.
12. Aronson J D, Aronson C F. Appraisal of the protective value of BCG vaccine. JAMA 1952; 149: 334-343.
13. Aronson J D, Aronson C F, Taylor H C. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. Arch Intern Med 1958; 101: 881-893.
14. Stein S C, Aronson J D. The occurrence of pulmonary lesions in BCG-vaccinated and unvacinated persons. Am Rev Tuberc 1953; 68: 695-712.
15. Rosenthal S R, Loewinsohn E, Graham M L, et al. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics 1961; 28: 622-641.
16. Rosenthal S R, Loewinsohn E, Graham M I, Liveright D, Thorne M G, Johnson V. BCG vaccination in tuberculous households. Am Rev Respir Dis 1961; 84: 690-704.
17. Comstock G W, Shaw L W. Controlled trial of BCG vaccination in a school population. Public Health Rep 1960; 75: 583-594.
18. Comstock G W, Webster R G. Tuberculosis studies in Muscogee County, Georgia. VII. A twenty year evaluation of BCG vaccination in a school population Am Rev Respir Dis 1969; 100: 839-845.
19. Palmer C E, Shaw L W, Comstock G W. Community trials of BCG vaccination. Am Rev Tuberc Pulmonary Dis 1958; 77: 877-907.
20. Comstock G W, Livesay V T, Woolpert S F. Evaluation of BCG vaccination among Puerto Rican children. Am J Public Health 1974; 64: 283-291.
21. Comstock G W, Palmer C E. Long-term results of BCG vaccination in the Southern United States. Am Rev Respir Dis 1966; 93: 171-183.
22. Comstock G W, Woolpert S F, Livesay V T. Tuberculosis studies in Muscogee County, Georgia. Twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep 1976; 91: 276-280.
23. Comstock G W. Tuberculosis studies in Muscogee County, Georgia. I. Community-wide tuberculosis research. Public Health Rep 1949; 64: 259-263.
24. Medical Research Council. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescents: first (progress) report to the Medical Research Council. Brit Med J 1956; 1: 413-427.
25. Medical Research Council. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescents: second report. Brit Med J 1959; 2: 379-396.
26. Medical Research Council. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life: third report. Brit Med J 1963; 1: 973-978.
27. Medical Research Council. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life: fourth report. Bull World Health Organ 1972; 46: 371-385.
28. Frimodt-Moller J, Thomas J, Parthasarathy R. Observations on the protective effect of BCG vaccination in a South Indian rural population. Bull World Health Organ 1964; 30: 545-574.
29. Frimodt-Moller J, Acharyulu G S, Parthasarathy R. Observations on the protective effect of BCG vaccination in a South Indian rural population- third report. Ind J Tub 1968; 15: 40-46.
30. Frimodt-Moller J, Acharyulu G S, Pillai K K. Observations on the protective effect of BCG vaccination in a South Indian rural population: fourth report. Bull Int Union Tuberc 1973; 48: 40-50.
31. Tripathy S P. Fifteen-year follow-up of the Indian BCG prevention trial. Bull Int Union Tuberc Lung Dis 1987; 62(3): 69-72.
32. Tuberculosis Prevention Trial Madras. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J Med Res 1980; 72 (Suppl): 1-74.
33. Clemens J D, Chuong J J H, Feinstein A R. The BCG controversy. A methodological and statistical reappraisal. JAMA 1983; 249: 2362-2369.
34. Coetzee A M, Berjak J. BCG in the prevention of tuberculosis in an adult population. Proceedings of the Mine Medical Officers' Association 1968; 48: 41-53.
35. Vandiviere H M, Dworski M, Melvin I G, Watson K A, Begley J. Efficacy of bacillus Calmette-Guérin and isoniazid-resistant bacillus Calmette-Guérin with and without isoniazid chemoprophylaxis from day of vaccination. II. Field trial in man. Am Rev Respir Dis 1973; 108: 301-313.
36. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-188.
37. Thompson S G, Spector T D. The potential limitations of meta-analysis. J Epidemiol Community Health 1991; 45: 89-92.
38. Fine P E M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 1339-1345.
39. Springett V H, Sutherland I. A re-examination of the variations in the efficacy of BCG vaccination against tuberculosis in clinical trials Tubercle Lung Dis 1994; 75: 227-233.
40. Global Tuberculosis Programme and Global Programme on Vaccines. Statement on BCG revaccination for the prevention of tuberculosis. Weekly Epidemiol (WHO) Rec 1995; 70: 229-231.
41. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348: 17-24.
42. Ponnighaus J M, Fine P E M, Sterne J A C, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992; 339: 636-639.
43. Barreto M L, Dourado M I C, Martins S P, Rodrigues L C, Hijjar M A, Maia M L S. Avalicao da eficacia da segunda dose de BCG na idade escolar. IESUS 1997; V(1): 59-66.